<DOC>
	<DOCNO>NCT01240642</DOCNO>
	<brief_summary>The purpose study determine effect ASA404 infusion rate co-administrating ASA404 paclitaxel + carbopaltin chemotherapy regimen docetaxel pharamcokinetics ( PK ) free total ASA404 .</brief_summary>
	<brief_title>An Open-label , Dose Escalation Multi-center Study Patients With Advanced Cancer Determine Infusion Rate Effect ASA 404 With Paclitaxel Plus Carboplatin Regimen Docetaxel Pharmacokietics Free Total ASA404</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients histologicallyproven solid tumor , either refractory standard chemotherapy Patients chemotherapy investigaional agent combination docetaxel , paclitaxel + carboplatin appropriate Creatinine clearance accord CockcroftGault formula : Normal &gt; 80 mL/min , Mild 5080 mL/min , Moderate 30 &lt; 50 mL/min A minimum 4 week must elapse since last treatment cancer therapy Potassium , calcium , magnesium phosphorus value within normal range Body Mass Index ( BMI ) must within range 18 30 Patients CNS metastasis , must CT MRI brain perform rule CNS metastases Patients leptomeningeal disease metastasis Radiotherapy &lt; / week prior start study drug Major surgery &lt; / 4 week prior start study Administration CYP1A2 CYP3A4/5 enzyme induce inhibit drug within 14 day prior start study drug Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Advanced metastatic cancer</keyword>
	<keyword>refractory</keyword>
	<keyword>core phase</keyword>
	<keyword>extension phase</keyword>
	<keyword>dose escalation</keyword>
	<keyword>standard chemotherapy</keyword>
	<keyword>doctaxel</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
</DOC>